Clinical trial • Phase IV • Musculoskeletal

Ropivacaine hydrochloride for Hip osteoarthritis | Postoperative pain

Phase IV trial of Ropivacaine hydrochloride for Hip osteoarthritis | Postoperative pain.

Overview

Trial Therapeutic Area
Musculoskeletal
Trial Disease
Hip osteoarthritis | Postoperative pain
Trial Stage
Phase IV
Drug Modality
Small molecule

Key dates

Initial CTIS Submission Date
03-09-2025
First CTIS Authorization Date
31-10-2025

Trial design

Randomised, comparator arm: bicain spinal (bupivacaine hydrochloride) 5 mg/ml solution for intrathecal use (single-shot intrathecal bupivacaine; max total dose reported 13.5 mg) versus test arm: ropivacain fresenius kabi (ropivacaine hydrochloride) 5 mg/ml solution for intrathecal use (single-shot intrathecal ropivacaine; max total dose reported 16 mg).-controlled Phase IV trial across 1 site in Finland.

Randomised
Yes
Comparator
Comparator arm: Bicain Spinal (Bupivacaine hydrochloride) 5 mg/ml solution for intrathecal use (single-shot intrathecal bupivacaine; max total dose reported 13.5 mg) versus Test arm: Ropivacain Fresenius Kabi (Ropivacaine hydrochloride) 5 mg/ml solution for intrathecal use (single-shot intrathecal ropivacaine; max total dose reported 16 mg).
Target Sample Size
162

Eligibility

Recruits 162 Vulnerable population not selected. Exclusion criteria include 'Cognitive deficiencies preventing informed consent' and 'Language barrier preventing completion of study form in Finnish'. Informed consent must be understood and signed by participants..

Pregnancy Exclusion
Pregnancy or breastfeeding
Vulnerable Population
Vulnerable population not selected. Exclusion criteria include 'Cognitive deficiencies preventing informed consent' and 'Language barrier preventing completion of study form in Finnish'. Informed consent must be understood and signed by participants.

Inclusion criteria

  • {"criterion_text":"- 18 – 80 years of age\n- Scheduled for a primary elective total hip arthroplasty\n- Patient must be a candidate for same day discharge as determined by local guidelines that will be published separately (incl. ASA 1-2, BMI < 35)\n- Informed consent understood and signed\n- Patient is 160 -186 cm tall"}

Exclusion criteria

  • {"criterion_text":"- Scheduled bilateral THA\n- Language barrier preventing completion of study form in Finnish\n- Pregnancy or breastfeeding\n- Chronic pain syndrome\n- Contraindication to or failed spinal anesthesia\n- Allergy or contraindication to NSAIDs (e.g. chronic anti-coagulant use)\n- Diabetes requiring insulin medication\n- Preoperative chronic use of illegal substances\n- Renal insufficiency (eGFR < 60)\n- Unstable psychiatric conditions\n- Severe neurological disorder\n- Cognitive deficiencies preventing informed consent"}

Endpoints

Primary endpoints

  • {"endpoint_text":"- Return of sensory and motor function","definition_or_measurement_approach":""}

Secondary endpoints

  • {"endpoint_text":"- Post-operative pain evaluated using the Numeric Rating Scale (NRS)","definition_or_measurement_approach":"Measured using the Numeric Rating Scale (NRS)"}
  • {"endpoint_text":"- Urinary retention","definition_or_measurement_approach":""}
  • {"endpoint_text":"- Post-operative nausea and vomiting","definition_or_measurement_approach":""}
  • {"endpoint_text":"- Postoperative opioid consumption in morphine milligram equivalents (MME)","definition_or_measurement_approach":"Measured as opioid consumption converted to morphine milligram equivalents (MME)"}
  • {"endpoint_text":"- Patient satisfaction will be evaluated using a 5-point Likert scale","definition_or_measurement_approach":"Measured using a 5-point Likert scale"}
  • {"endpoint_text":"- Perioperative hemodynamics","definition_or_measurement_approach":""}
  • {"endpoint_text":"- Onset time of block","definition_or_measurement_approach":"Time to onset of sensory/motor block (as stated)"}
  • {"endpoint_text":"- Adequacy of anesthesia","definition_or_measurement_approach":""}
  • {"endpoint_text":"- Same day discharge rate","definition_or_measurement_approach":"Proportion of patients discharged same day"}
  • {"endpoint_text":"- Length of stay in the postoperative care unit and length of hospital stay","definition_or_measurement_approach":"Measured as duration/time in postoperative care unit and total hospital stay"}

Recruitment

Planned Sample Size
162
Recruitment Window Months
13
Consent Approach
Informed consent must be understood and signed by the participant. Subject information and consent documents are present (document titles indicate Finnish language availability); exclusion exists for 'Language barrier preventing completion of study form in Finnish.' Participants (aged 18–80) provide consent themselves; no paediatric assent procedures are applicable.

Geography

Total Number Of Sites
1
Total Number Of Participants
162

Finland

Earliest CTIS Part Ii Submission Date
19-10-2025
Latest Decision Or Authorization Date
30-04-2026
Processing Time Days
193
Number Of Sites
1
Number Of Participants
162

Sites

Site Name
Turku University Hospital
Department Name
Anesthesiology and Intensive Care
Principal Investigator Name
Panu Uusalo
Principal Investigator Email
pijuus@utu.fi
Contact Person Name
Panu Uusalo
Contact Person Email
pijuus@utu.fi
Number Of Participants
162

Sponsor

Primary sponsor

Full Name
Turku University Hospital
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
Finland

Third parties

  • {"country":"","full_name":"Finnish State Research Funding (VTR) for university level health research.","duties_or_roles":"Source of monetary support","organisation_type":""}

Investigational products

Investigational Product Name
Ropivacain Fresenius Kabi 5 mg/ml injektioneste, liuos
Active Substance
Ropivacaine hydrochloride
Modality
Small molecule
Routes Of Administration
Intrathecal
Route
Intrathecal
Authorisation Status
Authorised (marketing authorisation: 27493)
Frequency
Single-shot
Maximum Dose
16 mg
Investigational Product Name
Bicain Spinal 5 mg/ml injektioneste, liuos
Active Substance
Bupivacaine hydrochloride
Modality
Small molecule
Routes Of Administration
Intrathecal
Route
Intrathecal
Authorisation Status
Authorised (marketing authorisation: 12054)
Frequency
Single-shot
Maximum Dose
13.5 mg

Related trials

Other published trials that may interest you.